Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedSep 14, 2026
DataAggregated Company Financials
Companies1377
  • 7D-3.8%
  • 3M8.7%
  • 1Y22.2%
  • YTD7.1%

Over the last 7 days, the Healthcare industry has dropped 3.8%, driven by pullbacks in Amgen and Eli Lilly of 14% and 2.9%, respectively. On the other hand HCA Healthcare is actually up 5.4%. This takes the industry's 12 month performance to a gain of 21%. Earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 14 Sep 2026US$7.0tUS$3.4tUS$118.8b24.9x58.7x2.1x
Wed, 12 Aug 2026US$7.1tUS$3.4tUS$116.1b26x61.6x2.1x
Fri, 10 Jul 2026US$7.0tUS$3.3tUS$122.0b25.2x57.1x2.1x
Sun, 07 Jun 2026US$6.4tUS$3.3tUS$122.6b23.6x52.5x1.9x
Tue, 05 May 2026US$6.2tUS$3.3tUS$117.9b23.6x52.4x1.9x
Thu, 02 Apr 2026US$6.2tUS$3.3tUS$128.2b22.7x48x1.9x
Sat, 28 Feb 2026US$6.6tUS$3.3tUS$126.9b25.6x51.9x2x
Mon, 26 Jan 2026US$6.6tUS$3.2tUS$130.6b28.5x50.6x2.1x
Wed, 24 Dec 2025US$6.5tUS$3.2tUS$135.2b26.3x48.4x2x
Fri, 21 Nov 2025US$6.3tUS$3.2tUS$133.1b25x47.1x2x
Sun, 19 Oct 2025US$6.0tUS$3.1tUS$140.4b24.8x42.5x1.9x
Tue, 16 Sep 2025US$5.7tUS$3.1tUS$137.5b23.6x41.7x1.9x
Thu, 14 Aug 2025US$5.4tUS$3.1tUS$140.7b24.1x38.7x1.8x
Sat, 12 Jul 2025US$5.6tUS$3.0tUS$127.9b24.4x43.5x1.8x
Mon, 09 Jun 2025US$5.5tUS$3.0tUS$127.2b24x43.2x1.8x
Wed, 07 May 2025US$5.5tUS$2.7tUS$125.5b24.5x44.1x2x
Fri, 04 Apr 2025US$5.6tUS$2.6tUS$82.0b25.6x68.2x2.1x
Sun, 02 Mar 2025US$5.9tUS$2.6tUS$79.3b27.5x74x2.2x
Tue, 28 Jan 2025US$6.1tUS$2.9tUS$85.5b28.4x70.8x2.1x
Thu, 26 Dec 2024US$5.9tUS$2.9tUS$78.3b26.9x74.8x2x
Sat, 23 Nov 2024US$6.0tUS$2.9tUS$77.3b28.3x77.9x2.1x
Mon, 21 Oct 2024US$6.2tUS$2.8tUS$58.8b32.2x106.2x2.2x
Wed, 18 Sep 2024US$6.3tUS$2.8tUS$60.1b31.2x105.5x2.2x
Fri, 16 Aug 2024US$6.1tUS$2.8tUS$55.7b31.3x109.4x2.2x
Sun, 14 Jul 2024US$6.3tUS$2.8tUS$62.2b31.2x101.7x2.2x
Tue, 11 Jun 2024US$6.2tUS$2.8tUS$63.6b30x97.9x2.2x
Thu, 09 May 2024US$6.1tUS$2.8tUS$65.4b30.7x93.4x2.2x
Sat, 06 Apr 2024US$6.1tUS$2.8tUS$83.9b32.4x72.7x2.2x
Mon, 04 Mar 2024US$6.3tUS$2.8tUS$85.0b31.2x74.2x2.3x
Wed, 31 Jan 2024US$6.4tUS$2.8tUS$80.0b31.9x79.7x2.3x
Fri, 29 Dec 2023US$6.2tUS$2.8tUS$91.5b32.8x68x2.2x
Sun, 26 Nov 2023US$5.9tUS$2.8tUS$91.4b28.6x64.4x2.1x
Tue, 24 Oct 2023US$5.7tUS$2.8tUS$99.6b24.8x57.3x2x
Thu, 21 Sep 2023US$6.0tUS$2.8tUS$98.6b28.2x60.7x2.2x
Price to Earnings Ratio

60.7x


Total Market Cap: US$6.0tTotal Earnings: US$98.6bTotal Revenue: US$2.8tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 58.7x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 6.4% per year over the last three years.
  • Revenues for these companies have grown 6.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-0.94%
Healthcare-3.76%
Healthcare Services-1.82%
Life Sciences-1.94%
Pharma-3.39%
Healthtech-4.09%
Biotech-5.21%
Medical Equipment-5.53%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 55.3x.
    • Analysts are expecting annual earnings growth of 18.6%, which is higher than its past year's earnings growth of 9.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 29% over the next 5 years.
  • However this is lower than its past earnings growth rate of 65% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
HCA HCA HealthcareUS$426.945.4%
+US$4.8b		5.9%PE13.5x
ROIV Roivant SciencesUS$40.8216.9%
+US$4.3b		192.6%PS3914.7x
ELV Elevance HealthUS$418.722.8%
+US$2.4b		36.4%PE18.3x
ABBV AbbVieUS$257.120.3%
+US$1.2b		18.2%PE72.5x
HUM HumanaUS$409.802.1%
+US$991.9m		48.8%PE38.5x

Latest News

ABBV
US$257.12
AbbVie
7D
0.3%
1Y
18.2%
JNJ
US$265.58
Johnson & Johnson
7D
-3.5%
1Y
49.7%
ROIV
US$40.82
Roivant Sciences
7D
16.9%
1Y
192.6%
Seeking Alpha • 21h

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

Summary LISRAYA’s recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV’s pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3 plays out. Overall, I think ROIV’s valuation still seems compelling if we assume management ultimately delivers on their long-term peak sales targets. Read the full article on Seeking Alpha
LLY
US$1,115.70
Eli Lilly
7D
-2.9%
1Y
49.1%
TXG
US$68.59
10x Genomics
7D
9.5%
1Y
413.8%
MRK
US$143.93
Merck
7D
-4.3%
1Y
77.6%
SYK
US$275.56
Stryker
7D
-9.1%
1Y
-26.9%
Narrative Update • Sep 09

SYK: Hospital Digitization And Cyber Resilience Will Underpin Post Cyberattack Recovery

Stryker's updated analyst price target has edged lower in line with a reduced fair value estimate of about $376, as analysts weigh slightly softer revenue growth and profit margin assumptions, along with a more conservative future P/E outlook following recent revisions across the MedTech coverage group. Analyst Commentary Recent Street research on Stryker shows a mix of confidence in the company’s long term growth drivers and concern about near term execution risks, especially around 2026 guidance and the impact of operational disruptions.
TEVA
US$37.09
Teva Pharmaceutical Industries
7D
2.0%
1Y
96.3%
Narrative Update • Sep 09

TEVA: Celiac And Vitiligo Data Are Expected To Drive Neuroscience Pivot

Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries to $41.91 from $40.90, citing stronger assumed revenue growth, a slightly higher future P/E multiple, and recent Street research that highlights commercial execution and a maturing pipeline in areas such as celiac disease and Tourette's syndrome. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries focuses on how the company is executing on its growth plans and how that might support current valuation levels.
UNH
US$379.09
UnitedHealth Group
7D
-4.5%
1Y
9.0%
HCA
US$426.94
HCA Healthcare
7D
5.4%
1Y
5.9%
AMGN
US$377.35
Amgen
7D
-13.7%
1Y
37.5%
GILD
US$143.72
Gilead Sciences
7D
-4.8%
1Y
27.7%
ISRG
US$369.15
Intuitive Surgical
7D
0.7%
1Y
-14.9%
ABT
US$101.95
Abbott Laboratories
7D
-5.9%
1Y
-22.4%
HUM
US$409.80
Humana
7D
2.1%
1Y
48.8%
Narrative Update • Sep 04

HUM: Medicare Advantage Margin Recovery Will Depend On Stars And Cost Trends

Humana's analyst fair value estimate has shifted from about $308 to roughly $419. This reflects higher Street price targets and analyst views that improving cost trends, margin recovery efforts and clearer earnings visibility support a richer assumed profit margin and P/E multiple, even with more modest revenue growth assumptions.
ELV
US$418.72
Elevance Health
7D
2.8%
1Y
36.4%